CSS
TEVA icon

Cubist Systematic Strategies’s Teva Pharmaceuticals TEVA Stock Holding History

Cubist Systematic Strategies’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$107K Sell
5,300
-77,800
-94% -$1.37M ﹤0.01% 2766
2025
Q2 		$1.39M Buy
+83,100
New +$1.34M 0.01% 1760
2024
Q1 		– Sell
-18,300
Closed -$191K – 4262
2023
Q4 		$191K Hold
18,300
– – ﹤0.01% 3020
2023
Q3 		$187K Hold
18,300
– – ﹤0.01% 2809
2023
Q2 		$138K Sell
18,300
-78,000
-81% -$632K ﹤0.01% 2918
2023
Q1 		$852K Sell
96,300
-23,200
-19% -$229K 0.01% 2298
2022
Q4 		$1.09M Buy
+119,500
New +$1.04M 0.01% 2367

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Cubist Systematic Strategies's TEVA Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 190,244 shares — an estimated $3.43M sold.

Cubist Systematic Strategies first reported a position in TEVA in Q2 2014 and held it in 41 quarters. The position peaked at $8.96M in Q2 2023. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 190,244 Teva Pharmaceuticals shares in Q4 2024, an estimated $3.43M.
  • Cubist Systematic Strategies first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 41 quarters.
  • Cubist Systematic Strategies's Teva Pharmaceuticals position peaked at $8.96M in Q2 2023.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.